Abstract
We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Benzamides
-
Disease-Free Survival
-
Drug Resistance, Neoplasm / drug effects*
-
Female
-
Humans
-
Imatinib Mesylate
-
Italy
-
Leukemia, Myeloid, Acute / diagnosis
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / mortality
-
Male
-
Middle Aged
-
Piperazines / administration & dosage*
-
Piperazines / adverse effects
-
Proto-Oncogene Proteins c-kit*
-
Pyrimidines / administration & dosage*
-
Pyrimidines / adverse effects
-
Survival Rate
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Proto-Oncogene Proteins c-kit